表紙
市場調查報告書

神經病變治療藥的全球市場:2019年∼2023年

Neurologic Disorders Therapeutics Market by Application and Geography - Global Forecast and Analysis 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 906343
出版日期 內容資訊 英文 137 Pages
訂單完成後即時交付
價格
Back to Top
神經病變治療藥的全球市場:2019年∼2023年 Neurologic Disorders Therapeutics Market by Application and Geography - Global Forecast and Analysis 2019-2023
出版日期: 2019年08月13日內容資訊: 英文 137 Pages
簡介

全球神經病變治療藥市場上,新藥的認證,聯盟、合作,生活方式的變化等成為成長促進因素,在預測期間內預計將以約5%的年複合成長率擴大。但,不確實的神經刺激設備的出現,主要的神經病學的徵兆中學名藥的優勢,及神經病變相關的社會的歧視眼光等,可能妨礙在預測期間內神經病變治療藥產業的成長。

本報告提供全球神經病變治療藥市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 對手的威脅
  • 市場情況

第6章 市場區隔:各應用領域

  • 市場區隔:各應用領域
  • 各應用領域較:市場規模及預測(2018年∼2023年)
  • CNS
  • PNS
  • 市場機會:各應用領域

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 再生醫療的登場
  • 神經退化適應症的診斷的進步
  • 藥物的再處方

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Biogen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31875

About this market

Technavio's neurologic disorders therapeutics market analysis considers sales from both CNS and PNS. Our analysis also considers the sales of neurologic disorders therapeutics in Asia, Europe, North America, and ROW. In 2018, the CNS segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as recent drug approvals, the increasing geriatric population will play a significant role in the CNS segment to maintain its market position. Also, our global neurologic disorders therapeutics market report looks at factors such as approval of novel drugs, alliances, and collaborations, and changing lifestyle. However, uncertainties in the advent of neurostimulation devices, the dominance of generics in major neurologic indications, and social stigma associated with neurologic disorders may hamper the growth of the neurologic disorders therapeutics industry over the forecast period.

Overview

Approval of novel drugs

The global neurologic disorders therapeutics market is expected to benefit significantly from the recent approvals of various novel drugs for the treatment of major indications. Multiple sclerosis is a widely researched neurological disorder, and several drugs were approved in recent years for the treatment of the indication. Vendors have been conducting studies for the development of disease-modifying drugs for the treatment of the indication, which is expected to cater to the unmet need in the market. This will lead to the expansion of the global neurologic disorders' therapeutics market at a CAGR of almost 5% during the forecast period.

Advances in the diagnosis of neurogenerative indications

One of the major challenges faced by the global neurological disorders' therapeutics market is the lack of effective diagnostic processes for neurodegenerative indications. Hence the need for the development of biomarkers for the indication can lead to early diagnosis and help detect the progression of the disease accurately. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global neurologic disorders therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global neurologic disorders therapeutics market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neurologic disorders therapeutics manufacturers, that include Biogen Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc.

Also, the neurologic disorders therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

  • Market segmentation by application
  • Comparison by application
  • CNS - Market size and forecast 2018-2023
  • PNS - Market size and forecast 2018-2023
  • Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Advent of regenerative medicines
  • Advances in diagnosis of neurodegenerative indications
  • Drug reformulations

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Biogen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ billions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Application - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by application
  • Exhibit 20: CNS - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 21: CNS - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: PNS - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 23: PNS - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by application
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ billions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: Biogen Inc. - Vendor overview
  • Exhibit 49: Biogen Inc. - Business segments
  • Exhibit 50: Biogen Inc. - Organizational developments
  • Exhibit 51: Biogen Inc. - Geographic focus
  • Exhibit 52: Biogen Inc. - Key offerings
  • Exhibit 53: Biogen Inc. - Key customers
  • Exhibit 54: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 55: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 56: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 57: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 58: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 59: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 60: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 61: Johnson & Johnson Services Inc. - Vendor overview
  • Exhibit 62: Johnson & Johnson Services Inc. - Business segments
  • Exhibit 63: Johnson & Johnson Services Inc. - Organizational developments
  • Exhibit 64: Johnson & Johnson Services Inc. - Geographic focus
  • Exhibit 65: Johnson & Johnson Services Inc. - Segment focus
  • Exhibit 66: Johnson & Johnson Services Inc. - Key offerings
  • Exhibit 67: Johnson & Johnson Services Inc. - Key customers
  • Exhibit 68: Novartis AG - Vendor overview
  • Exhibit 69: Novartis AG - Business segments
  • Exhibit 70: Novartis AG - Organizational developments
  • Exhibit 71: Novartis AG - Geographic focus
  • Exhibit 72: Novartis AG - Segment focus
  • Exhibit 73: Novartis AG - Key offerings
  • Exhibit 74: Novartis AG - Key customers
  • Exhibit 75: Pfizer Inc. - Vendor overview
  • Exhibit 76: Pfizer Inc. - Business segments
  • Exhibit 77: Pfizer Inc. - Organizational developments
  • Exhibit 78: Pfizer Inc. - Geographic focus
  • Exhibit 79: Pfizer Inc. - Segment focus
  • Exhibit 80: Pfizer Inc. - Key offerings
  • Exhibit 81: Pfizer Inc. - Key customers
  • Exhibit 82: Validation techniques employed for market sizing
  • Exhibit 83: Definition of market positioning of vendors
Back to Top